Thrombolytic Therapies: The Current State of Affairs

摘要: Thrombotic occlusive diseases are manifested in several disorders that have significant morbidity and mortality, including acute myocardial infarction, pulmonary embolism, deep venous thrombosis, cerebrovascular accidents. This review summarizes the recently published literature covering thrombolytic therapies these diseases, with particular attention to comparisons between fibrin-specific tissue plasminogen activators (alteplase, reteplase, tenecteplase) nonfibrin-specific (streptokinase or urokinase activator). These agents act convert plasmin, which turn cleaves fibrin as part of lysis process. Fibrin-specific were anticipated be more efficacious safer than nonspecific because their pathophysiologically restricted mechanism action. However, also lyse physiological hemostatic plugs, can result costly adverse events. Efficacy has been shown generally equivalent, similar mortality rates compared agents; however, may associated an increased incidence intracerebral hemorrhage costs. Therefore, it appears given equivalent efficacy, activators, such streptokinase urokinase, a choice many thrombotic situations.